AcuCort reports positive results from the company’s questionnaire study about allergy treatments
AcuCort AB (publ) (Spotlight Stock Market: ACUC) reports today positive results from the company's questionnaire study on how allergy patients value their treatment. The results from the study will be included in the documentation in AcuCort's upcoming pricing and reimbursement application to the Swedish Dental and Pharmaceutical Benefits Agency, TLV.The questionnaire study includes a total of 426 patients who have answered questions about their allergy and how they value the available treatment options. From the beginning, just over 100 patients would have been included in the study, but